| Bioactivity | Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes[1]. | ||||||
| Target | Glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor | ||||||
| Name | Tirzepatide TFA | ||||||
| Shortening | Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2 | ||||||
| Formula | C227H349F3N48O70 | ||||||
| Molar Mass | 4927.47 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
| Reference | [1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. |
Tirzepatide TFA
CAS: F: C227H349F3N48O70 W: 4927.47
Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.